{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-008429","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.096901+00:00","generated_at":"2026-06-17T10:00:32.913294+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dyadic reports 2022 revenue up 21.9% to $2.93M; net loss narrows to $9.7M; COVID-19 vaccine trial dosing complete","bullets":["Revenue $2.93M (+21.9% YoY); net loss $9.7M ($0.34/share) vs $13.1M ($0.47) in 2021.","Cash $12.7M at year-end; received $1.27M from Alphazyme sale in Jan 2023; expects to fund ops into 2024.","Phase 1 trial of DYAI-100 COVID-19 booster: dosing complete in low/high dose groups, no serious adverse events; full report H2 2023.","Collaborations with Janssen, Phibro/Abic, global food ingredient company; Dapibus platform progress.","Five peer-reviewed publications on C1-cell platform; new corporate website."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-008429","json":"https://secwatch.observer/filing/0001437749-23-008429.json","markdown":"https://secwatch.observer/filing/0001437749-23-008429.md","text":"https://secwatch.observer/filing/0001437749-23-008429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923008429/0001437749-23-008429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923008429/dyai20221121_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:00:32.913294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e9d1b7b0f3e2b5aebe72b2c3e010054946b4952","claim":"DYADIC INTERNATIONAL INC reported financial results for year ended December 31, 2022.","evidence_excerpt":"On March 29, 2023, Dyadic International, Inc. (“Dyadic”, or the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and recent Company progress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference except for paragraphs two, three, four and five of the press release.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923008429/0001437749-23-008429-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}